BioSyent Inc. (V:RX)

Business Focus: Pharmaceuticals (NEC)

Get the company report for the most recent outlook updated daily

Apr 23, 2024 05:45 pm ET

BioSyent to Attend Planet MicroCap Showcase

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th – May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of...

Apr 15, 2024 04:31 pm ET

BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner...

Apr 10, 2024 08:30 am ET

BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre...

Apr 03, 2024 08:00 am ET

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based on a national survey of Canadian pharmacists and physicians(1). This year marks the ninth consecutive year...

Apr 01, 2024 02:00 pm ET

BioSyent to Present at LD Micro New York Investor Conference

BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person at the LD Micro Invitational XIV Conference in New York City on Tuesday, April 9th at 8:00am...

Mar 27, 2024 06:34 pm ET

BioSyent Announces Grant of Restricted Share Units

BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the...

Mar 13, 2024 05:30 pm ET

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023. Key highlights include: (CAD)Q4 2023% Change vs. Q4 2022FY 2023% Change vs. FY 2022Canadian...

Mar 06, 2024 04:30 pm ET

BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2023 on Wednesday, March 13th after market hours. A presentation on the Company’s fourth...

Feb 21, 2024 08:00 am ET

BioSyent Named to 2024 TSX Venture 50

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top performers on the TSX Venture Exchange. The TSX Venture 50 is an annual ranking of the top...

Feb 06, 2024 04:30 pm ET

BioSyent Declares First Quarter 2024 Dividend

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at...

Dec 13, 2023 08:00 am ET

BioSyent Announces Renewal of Normal Course Issuer Bid

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent...

Nov 20, 2023 08:30 am ET

BioSyent Announces the Availability of Gelclair® in Canada

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of its new oncology supportive care product, Gelclair®, to wholesalers in Canada....

Nov 16, 2023 08:00 am ET

BioSyent Releases Q3 and YTD 2023 Financial Results

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2023. Key highlights include: (CAD)Q3 2023% Change vs. Q3 2022YTD 2023% Change vs. YTD...

Nov 15, 2023 04:34 pm ET

BioSyent Declares Fourth Quarter 2023 Dividend

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record...

Nov 09, 2023 08:00 am ET

BioSyent Schedules Q3 and YTD 2023 Earnings Release for November 16, 2023

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2023 on Thursday, November 16, 2023 before market hours. A presentation on the Company’s third...

Oct 18, 2023 08:00 am ET

BioSyent Launches "menopauseinformation.ca" on World Menopause Day

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce the launch of menopauseinformation.ca, a comprehensive online platform designed to empower peri-menopausal and menopausal women across Canada. Menopause is a natural transition...

Aug 23, 2023 08:22 pm ET

TSX Venture Exchange Stock Maintenance Bulletins

VANCOUVER, BC, Aug. 23, 2023 /CNW/ -

Aug 22, 2023 04:15 pm ET

BioSyent Releases Q2 and H1 2023 Financial Results

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2023. Key highlights include: Second quarter (Q2) 2023 Total Company Net Revenues of $7,962,800 increased by 20% versus...

Aug 22, 2023 04:01 pm ET

BioSyent Declares Third Quarter 2023 Dividend

Aug 15, 2023 04:30 pm ET

BioSyent Schedules Q2 and H1 2023 Earnings Release for August 22, 2023

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2023 on Tuesday, August 22, 2023 after market close. A presentation on the Company’s second quarter and...

Aug 08, 2023 08:00 am ET

BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of Inofolic® to the Canadian marketplace. Inofolic® is a natural health product, combining myo-inositol...

Jul 06, 2023 05:53 pm ET

BioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck Cancer

BioSyent Pharma Inc. (“BioSyent Pharma”), a subsidiary of BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX), is attending the American Head and Neck Society (AHNS) 11th International Conference on Head and Neck Cancer in Montreal, Quebec...

Jun 20, 2023 08:30 am ET

BioSyent Announces Long-term Extension of Cathejell® Agreement

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its License, Distribution and Supply Agreement with its European partner for...

May 31, 2023 05:42 pm ET

BioSyent Announces Approval of New Product

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received regulatory approval from Health Canada for a new oncology supportive care product. BioSyent Pharma Inc. signed...

May 26, 2023 08:00 am ET

BioSyent Releases Financial Results for Q1 2023

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2023. Key highlights include: First quarter (Q1) 2023 Canadian Pharmaceutical Net Revenues of $6,411,694 increased by 1%...

May 25, 2023 05:40 pm ET

BioSyent Declares Second Quarter 2023 Dividend

May 18, 2023 08:30 am ET

BioSyent Schedules Q1 2023 Earnings Release for May 26, 2023

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2023 on Friday, May 26, 2023 at 8:00am ET. A presentation on the Company’s first quarter 2023 results by René...

May 02, 2023 02:59 pm ET

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians, Eight Years Running!

Apr 18, 2023 09:15 am ET

BioSyent to Present at 2023 Bloom Burton & Co. Healthcare Investor Conference

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2023 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre...

Mar 31, 2023 05:42 pm ET

BioSyent Announces Grant of Restricted Share Units

BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 72,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the...

Mar 21, 2023 04:30 pm ET

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2022

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2022. Key highlights include: Fourth quarter (Q4) 2022 Total Company Net Revenues of $7,461,930 increased by 3%...

Mar 09, 2023 04:30 pm ET

BioSyent Schedules Q4 and Full Year 2022 Earnings Release for March 21, 2023

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2022 on Tuesday, March 21, 2023 after market close. A presentation on the Company’s fourth...

Mar 07, 2023 04:01 pm ET

BioSyent Announces Launch of New FeraMAX® Pd Maintenance 45

On the eve of International Women’s Day, BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) celebrates the Canadian launch of FeraMAX® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX® Pd Maintenance 45 is BioSyent’s third...

Feb 01, 2023 04:30 pm ET

BioSyent Declares First Quarter 2023 Dividend

Dec 14, 2022 04:50 pm ET

BioSyent Signs Exclusive Agreement for Oncology Supportive Care Product

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive Distribution Agreement with a European partner for a product that is used in oncology supportive...

Dec 13, 2022 08:00 am ET

BioSyent Announces Renewal of Normal Course Issuer Bid

Nov 16, 2022 07:07 pm ET

BioSyent Releases Q3 and YTD 2022 Financial Results

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2022. Key highlights include: Third quarter (Q3) 2022 Total Company Net Revenues of $6,790,971 increased...

Nov 10, 2022 09:00 am ET

BioSyent Schedules Q3 and YTD 2022 Earnings Release for November 16, 2022

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2022 on Wednesday, November 16, 2022 after market hours. A presentation on the Company’s third...

Oct 12, 2022 05:45 pm ET

BioSyent Initiates First Dividend

Sep 14, 2022 04:30 pm ET

BioSyent to Present at the Virtual MicroCap Leadership Summit

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been selected to present at the 7th annual MicroCap Leadership Summit on Friday, September 16th, 2022. Mr. René Goehrum, President and CEO of BioSyent,...

Aug 23, 2022 04:55 pm ET

BioSyent Announces Adoption of Dividend Policy

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors (the “Board”) today adopted a Dividend Policy in order to establish terms of reference for the Board in its decision-making around the...

Aug 23, 2022 04:45 pm ET

BioSyent Releases Q2 and H1 2022 Financial Results

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2022. Key highlights include: Second quarter (Q2) 2022 Total Company Net Revenues of $6,634,875 decreased by 9% versus Q2...

Aug 16, 2022 07:14 pm ET

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2022 on Tuesday, August 23, 2022 after market hours. A presentation on the Company’s second quarter and...

May 18, 2022 08:00 am ET

BioSyent Releases Financial Results for Q1 2022

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2022. Key highlights include: First quarter (Q1) 2022 Net Revenues of $7,037,411 decreased by 5% versus Q1 2021Q1 2022...

May 10, 2022 04:30 pm ET

BioSyent Schedules Q1 2022 Earnings Release for May 18, 2022

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2022 on Wednesday, May 18, 2022 at 8:00am ET. A presentation on the Company’s first quarter 2022 results by René...

May 02, 2022 08:00 am ET

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Seventh Consecutive Year

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the seventh consecutive year, FeraMAX® is the #1 recommended iron supplement brand in Canada based on a national survey of Canadian pharmacists and physicians.1 This...

Apr 26, 2022 04:30 pm ET

BioSyent to Present at 2022 Bloom Burton & Co. Healthcare Investor Conference

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2022 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre...

Mar 31, 2022 04:55 pm ET

BioSyent Announces Grant of Restricted Share Units

BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 56,957 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the...

Mar 29, 2022 05:37 pm ET

FAX Capital Corp. Reports Fourth Quarter and 2021 Results

FAX Capital Corp. (FAX Capital or the Company) (TSX: FXC) today announced its results for the fourth quarter and full year ended December 31, 2021. All currency figures are Canadian dollars. Despite heightened market volatility in the latter half...

Mar 09, 2022 04:34 pm ET

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2021

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2021. Key highlights include: Fourth quarter (Q4) 2021 Net Revenues of $7,218,656 increased by 26% versus Q4...

Mar 03, 2022 04:28 pm ET

BioSyent Schedules Q4 and Full Year 2021 Earnings Release for March 9, 2022

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2021 on Wednesday, March 9, 2022 after market close. A presentation on the Company’s fourth...

Feb 11, 2022 09:29 am ET

BioSyent Adopts Advance Notice By-law

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that its Board of Directors has approved the adoption of an Advance Notice By-law (the “By-law”) for the purposes of: (i) facilitating an orderly and efficient annual general or,...

Dec 13, 2021 08:00 am ET

BioSyent Announces Renewal of Normal Course Issuer Bid

Nov 18, 2021 05:00 pm ET

BioSyent Releases Q3 and YTD 2021 Financial Results

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2021. Key highlights include: Third quarter (Q3) 2021 Net Revenues of $6,690,419 increased by 16% versus Q3...

Nov 10, 2021 08:00 am ET

BioSyent Schedules Q3 and YTD 2021 Earnings Release for November 18, 2021

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2021 on Thursday, November 18, 2021 at 5:00pm ET. A presentation on the Company’s third quarter and...

Oct 19, 2021 08:00 am ET

BioSyent Announces Launch of New FeraMAX® Pd Powder 15

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Powder 15 by its subsidiary, BioSyent Pharma Inc., in Canada. FeraMAX® Pd Powder 15 is the second product incorporating Polydextrose-Iron...

Aug 25, 2021 08:00 am ET

BioSyent Releases Q2 and H1 2021 Financial Results

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2021. Key highlights include: Second quarter (Q2) 2021 Net Revenues of $7,289,254 increased by 53% versus Q2 2020First...

Aug 17, 2021 08:00 am ET

BioSyent Schedules Q2 and H1 2021 Earnings Release for August 25, 2021

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2021 on Wednesday, August 25, 2021 at 8:00am ET. A presentation on the Company’s second quarter and first...

Aug 04, 2021 05:00 pm ET

FAX Capital Corp. Reports Second Quarter 2021 Results

FAX Capital Corp. (FAX Capital or the Company) (TSX: FXC and FXC.WT) today announced its results for the quarter ended June 30, 2021. All currency figures are Canadian dollars. The Company performed well during the period, and these results...

Jul 13, 2021 08:00 am ET

BioSyent Signs Exclusive Technology Agreement

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an agreement to license a unique technology application to support better treatment outcomes for patients with iron...

Jun 11, 2021 07:30 am ET

FAX Capital Announces Investment in BioSyent Inc., Files Early Warning Report

FAX Capital Corp. (FAX or the Company) (TSX: FXC & FXC.WT) is pleased to announce that it has acquired ownership of 902,000 common shares (the Shares) of BioSyent Inc. (BioSyent) (TSXV: RX) through the facilities of the Neo Exchange Inc. (the...

May 27, 2021 08:00 am ET

BioSyent Releases Financial Results for Q1 2021

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2021. Key highlights include: Record first quarter (Q1) 2021 Net Revenues of $7,419,889 increased by 22% versus Q1 2020Q1...

May 20, 2021 08:00 am ET

BioSyent Schedules Q1 2021 Earnings Release for May 27, 2021

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2021 on Thursday, May 27, 2021 at 8:00am EDT. A presentation on the Company’s first quarter 2021 results by René...

May 03, 2021 08:00 am ET

FeraMAX® Named #1 Recommended Iron Supplement by National Pharmacists and Physicians for Sixth Consecutive Year

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the sixth consecutive year, FeraMAX® has been named the #1 recommended iron supplement brand in a national survey of Canadian physicians and pharmacists. The 2021 OTC...

Apr 14, 2021 08:00 am ET

BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference. The conference will be held virtually on Tuesday, April 20 and Wednesday, April 21,...

Mar 19, 2021 05:33 pm ET

BioSyent Announces Grant of Restricted Share Units

BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 67,252 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the...

Mar 17, 2021 08:00 am ET

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2020

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2020. Key highlights include: Fourth quarter (Q4) 2020 Net Revenues of $5,726,328 increased by 3% versus...

Mar 16, 2021 07:01 am ET

Combogesic® - First Acetaminophen + Ibuprofen Combination Tablet - Now Available for Canadians with Acute Pain

New treatment option offers a clinically proven 3.3:1 acetaminophen to ibuprofen ratio

Mar 11, 2021 08:00 am ET

BioSyent Schedules Q4 and Full Year 2020 Earnings Release for March 17, 2021

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2020 on Wednesday, March 17, 2021. A presentation on the Company’s fourth quarter and full year...

Dec 16, 2020 09:30 am ET

BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Combination Tablet in Canada Now Available

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of Combogesic® to Canadian wholesalers. Combogesic® is the first fixed-dose combination...

Dec 11, 2020 08:00 am ET

BioSyent Announces Renewal of Normal Course Issuer Bid

Nov 26, 2020 08:00 am ET

BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2020. Key highlights include: Third quarter (Q3) 2020 Net Revenues of $5,771,739 decreased by 7% versus Q3...

Nov 17, 2020 08:00 am ET

BioSyent Schedules Q3 and YTD 2020 Earnings Release for November 26, 2020

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2020 on Thursday, November 26, 2020. A presentation on the Company’s third quarter and year-to-date...

Nov 05, 2020 08:00 am ET

Biosyent Announces Launch of New FeraMAX® Pd Therapeutic 150

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Therapeutic 150, the first new product incorporating FeraMAX® Pd, a new oral iron supplement delivery system, by its subsidiary BioSyent...

Oct 15, 2020 09:00 am ET

BioSyent Named to the Growth List Ranking of Canada’s Fastest-Growing Companies for Eighth Consecutive Year

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been included in the 32nd annual Growth List, the definitive ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s. The Growth List (formerly...

Oct 05, 2020 08:00 am ET

BioSyent Announces Introduction of New FeraMAX® Pd

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the introduction of FeraMAX® Pd, a new oral iron supplement formulation, by its subsidiary BioSyent Pharma Inc. FeraMAX® Pd is a patented delivery system for the...

Oct 01, 2020 09:25 am ET

BioSyent Signs Exclusive Agreement for New Women’s Health Product

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive License and Supply Agreement with a European partner for a new product in the women’s health market for Canada....

Aug 26, 2020 07:30 am ET

BioSyent Releases Q2 and H1 2020 Results

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30, 2020. Key highlights include: Second quarter (Q2) 2020 Net Revenues of $4,771,255 decreased by 7% versus Q2...

Aug 24, 2020 04:30 pm ET

BioSyent to Present at the LD 500 Virtual Conference

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 2:40 p.m. (ET). Mr. René Goehrum, President and CEO of BioSyent, will be...

Aug 24, 2020 04:30 pm ET

BioSyent to Present at The LD 500 Virtual Conference

MISSISSAUGA, ON / ACCESSWIRE / August 24, 2020 / BioSyent Inc. ("BioSyent", "the Company", OTC PINK:BIOYF, TSX-V:RX.V) today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 2:40 p.m. (ET). Mr. René Goehrum, President and CEO of BioSyent, will be presenting to a live virtual audience. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference on September 1st to 4th. These one-on-one meetings can be requested by registered attendees thr

Aug 17, 2020 08:30 am ET

BioSyent Schedules Q2 and H1 2020 Earnings Release for August 26, 2020

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2020 on Wednesday, August 26, 2020. A presentation on the Company’s second quarter and first half 2020...

Aug 05, 2020 09:00 am ET

LD Micro Announces Preliminary List of Presenters for the LD 500

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Jul 29, 2020 04:01 pm ET

BioSyent Announces the Availability of Tibella® (tibolone) in Canada

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced the Canadian launch and product availability of Tibella® (tibolone) for short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more...

May 28, 2020 08:00 am ET

BioSyent Releases Results for Q1 2020

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three months ended March 31, 2020. Key highlights include: First quarter (Q1) 2020 Net Revenues of $6,062,846 increased by 35% versus Q1 2019Q1...

May 21, 2020 08:00 am ET

BioSyent Schedules Q1 2020 Earnings Release For May 28, 2020

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2020 on Thursday, May 28, 2020. A presentation on the Company’s first quarter 2020 results by René Goehrum,...

May 01, 2020 09:00 am ET

FeraMAX® Named #1 Recommended Iron Supplement by National Pharmacists and Physicians for Fifth Consecutive Year

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the fifth consecutive year, FeraMAX® has been named the #1 recommended iron supplement brand in a national survey of Canadian pharmacists and physicians. The 2020 Survey...

Mar 31, 2020 07:41 pm ET

BIOSYENT ANNOUNCES GRANT OF RESTRICTED SHARE UNITS

BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved today a grant of 129,125 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant...

Mar 18, 2020 08:00 am ET

BioSyent Releases Results for Fourth Quarter and Full Year 2019

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and twelve months ended December 31, 2019. Key highlights include: Fourth quarter (Q4) 2019 Net Revenues of $5,569,286 decreased by 6%...

Mar 11, 2020 08:00 am ET

BIOSYENT SCHEDULES Q4 AND FULL YEAR 2019 EARNINGS RELEASE FOR MARCH 18, 2020

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and twelve months ended December 31, 2019 on Wednesday, March 18, 2020. A presentation on the Company’s fourth quarter and full year...

Mar 06, 2020 05:30 pm ET

BioSyent Announces Adoption of Restricted Share Unit Plan

BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a Restricted Share Unit Plan (the “RSU Plan”). The RSU Plan is established as a vehicle by which equity-based incentives may be...

Dec 11, 2019 08:00 am ET

BioSyent Announces Renewal of Normal Course Issuer Bid

Nov 25, 2019 05:00 pm ET

BioSyent Signs Exclusive Agreement for Pain Management Products

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive License and Supply Agreement (“the Agreement”) with AFT Pharmaceuticals (“AFT”, NSX: AFT, ASX: AFP) for a portfolio...

Nov 20, 2019 08:00 am ET

BioSyent Releases Results for Third Quarter and First Nine Months of 2019

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and nine months ended September 30, 2019. Key highlights include: Record third quarter (Q3) 2019 Net Revenues of $6,219,748 increased by...

Nov 12, 2019 08:00 am ET

BioSyent Schedules Q3 and YTD 2019 Earnings Release for November 20, 2019

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2019 on Wednesday, November 20, 2019. A presentation on the Company’s third quarter and...

Sep 12, 2019 09:00 am ET

BioSyent Named to the Growth 500 Ranking of Canada's Fastest-Growing Companies for Seventh Consecutive Year

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been named to the 31st annual Growth 500 ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s. The Growth 500 ranks Canada’s top private and...

Aug 23, 2019 08:00 am ET

BioSyent Releases Q2 and H1 2019 Results

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30, 2019. Key highlights include: Second quarter (Q2) 2019 Net Revenues of $5,156,476 decreased by 13%...

Aug 15, 2019 08:00 am ET

BioSyent Schedules Q2 and H1 2019 Earnings Release for August 23, 2019

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2019 on Friday, August 23, 2019. A presentation on the Company’s second quarter and first half 2019...

Jun 26, 2019 08:00 am ET

BioSyent Announces Withdrawal of Health Canada Submissions for Cardiovascular Products

BioSyent Inc. (“BioSyent”, TSX Venture: RX) announces that it has informed Health Canada that it will be withdrawing its New Drug Submissions for two cardiovascular products, subsequent to the Notice of Deficiency received from Health Canada...

Jun 17, 2019 03:19 pm ET

BioSyent to Present at Raymond James Life Sciences and MedTech Conference

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that Mr. René Goehrum, President and CEO of BioSyent, will be presenting at the 2019 Raymond James Life Sciences and MedTech Conference on Wednesday, June 19th at 10:55 AM ET at the...

May 29, 2019 08:00 am ET

BioSyent Releases Results for Q1 2019

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three months ended March 31, 2019. Key highlights include: First quarter (Q1) 2019 Net Revenues of $4,478,814 increased by 1% versus Q1 2018Q1...

May 21, 2019 08:00 am ET

BioSyent Schedules Q1 2019 Earnings Release for May 29, 2019

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2019 on Wednesday, May 29, 2019. A presentation on the Company’s first quarter 2019 results by René Goehrum,...

May 13, 2019 04:01 pm ET

BioSyent Announces Health Canada Approval of New Women’s Health Product

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Tibella® (tibolone), indicated for the short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one...

May 02, 2019 10:51 am ET

FeraMAX® Named #1 by Canadian Physicians and Pharmacists for Fourth Consecutive Year

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the fourth consecutive year, FeraMAX® has been named the #1 recommended iron supplement brand in a national survey of Canadian physicians and pharmacists. The 2019...

Mar 22, 2019 04:01 pm ET

BioSyent Announces Notice of Deficiency for Cardiovascular Products

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that it has been informed by Health Canada that the Company will receive a Notice of Deficiency (“NOD”) with respect to its New Drug Submissions of two cardiovascular products for...

Mar 20, 2019 08:00 am ET

BioSyent Releases Results for Fourth Quarter and Full Year 2018

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and twelve months ended December 31, 2018. Key highlights include: Fourth quarter (Q4) 2018 Net Revenues of $5,910,965 increased by 0.2%...

Mar 15, 2019 12:35 pm ET

BioSyent Schedules Q4 2018 Earnings Release for March 20, 2019

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and twelve months ended December 31, 2018 on Wednesday, March 20, 2019. A presentation on the Company’s fourth quarter 2018 results by...

Dec 04, 2018 08:00 am ET

BioSyent Announces Normal Course Issuer Bid

Nov 21, 2018 08:00 am ET

BioSyent Releases Results for Third Quarter and First Nine Months of 2018

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and nine months ended September 30, 2018. Key highlights include: Third quarter (Q3) 2018 Net Revenues of $5,259,493 decreased...

Nov 08, 2018 09:22 am ET

BioSyent Schedules Q3 2018 Earnings Release for November 21, 2018

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2018 on Wednesday, November 21, 2018. A presentation on the Company’s third quarter 2018 results...

Sep 13, 2018 09:00 am ET

BioSyent Named to the Growth 500 Ranking of Canada's Fastest-Growing Companies for Sixth Consecutive Year

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been named to the annual Growth 500 ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s. The Growth 500 ranks Canadian businesses on...

Sep 10, 2018 05:28 pm ET

BioSyent Announces Changes to Executive Management

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced changes to its Executive Management team: Effective on September 10, 2018, Mr. Alfred D’Souza has retired as Vice President, Finance and Chief Financial Officer of the...

Aug 24, 2018 12:00 pm ET

BioSyent to Present at Upcoming Investor Conference

BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture: RX) is pleased to announce that it will be presenting at the Midwest IDEAS Investor Conference at The Gwen in Chicago, Illinois. Mr. René Goehrum, BioSyent’s President and CEO, will...

Aug 22, 2018 08:00 am ET

BioSyent Releases Q2 and H1 2018 Results

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30, 2018. Key highlights include: Record second quarter (Q2) 2018 Net Revenues of $5,909,423 increased by 5%...

Aug 10, 2018 08:00 am ET

BioSyent Schedules Q2 2018 Earnings Release for August 22, 2018

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2018 on Wednesday, August 22, 2018. A presentation on the Company’s second quarter 2018 results by René...

May 30, 2018 08:00 am ET

BioSyent Releases Results for Q1 2018

BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three months ended March 31, 2018. Key highlights include: First quarter (Q1) 2018 Net Revenues of $4,447,147 increased by 16% versus Q1 2017Q1...

May 17, 2018 08:00 am ET

BioSyent Schedules Q1 2018 Earnings Release for May 30, 2018

BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture:RX) will be reporting its financial results for the first quarter ended March 31, 2018 on Wednesday, May 30, 2018. A presentation on the Company’s first quarter 2018 results by René Goehrum,...

May 01, 2018 08:00 am ET

FeraMAX® Named #1 by Canadian Physicians and Pharmacists for Third Consecutive Year

TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) is pleased to announce that for the third consecutive year, FeraMAX® has been named the #1 recommended iron supplement brand in a national survey of Canadian physicians...

Apr 25, 2018 11:45 am ET

BioSyent to Present at Upcoming Investor Conferences

TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) is pleased to announce that it will be presenting at the following upcoming investor conferences:

Mar 21, 2018 08:00 am ET

BioSyent Releases Results for Fourth Quarter and Full Year 2017

TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2017. Key highlights include:

Mar 08, 2018 08:00 am ET

BioSyent Schedules Fourth Quarter 2017 Earnings Release for March 21, 2018

TORONTO, March 08, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture:RX) will be reporting its financial results for the fourth quarter and fiscal year ended December 31, 2017 on Wednesday, March 21, 2018. A presentation...

Jan 08, 2018 06:09 pm ET

BioSyent Announces Changes to Its Board of Directors

TORONTO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) today announced the retirement of two long-serving Directors, Mr. Douglas Larson and Mr. Milton Wakefield, from its Board of Directors. BioSyent also announced the appointment of...

Nov 15, 2017 08:00 am ET

BioSyent Releases Results for Third Quarter and First Nine Months of 2017

TORONTO, Nov. 15, 2017 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three and nine months ended September 30, 2017. Key highlights include:

Nov 08, 2017 03:29 pm ET

BioSyent Schedules Q3 2017 Earnings Release for November 15, 2017

TORONTO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) will be reporting its financial results for the three and nine months ended September 30, 2017 on Wednesday, November 15, 2017 at 8:00am (ET). A presentation...

Aug 16, 2017 10:45 am ET

BioSyent Releases Q2 and H1 2017 Results - CORRECTION

TORONTO, Aug. 16, 2017 (GLOBE NEWSWIRE) -- BioSyent Inc.’s (“BioSyent”) (TSX Venture:RX) press release issued at 8:00am ET on August 16, 2017 contained erroneous information regarding the grant of incentive stock options. This press release has been revised with corrected information regarding the grant of incentive stock options:...

May 25, 2017 08:00 am ET

BioSyent Releases Q1 2017 Results

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three months ended March 31, 2017. Key highlights include:

May 25, 2017 07:58 am ET

BioSyent Releases Q1 2017 Results

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three months ended March 31, 2017. Key highlights include: First quarter (Q1) 2017 Net Revenues of $3,821,262...

May 16, 2017 08:00 am ET

BioSyent Schedules Q1 2017 Earnings Release for May 25, 2017

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) will be reporting its financial results for the three months ended March 31, 2017 on Thursday, May 25, 2017 at 8:00am (ET). A presentation on the Company's first quarter 2017 results by Mr. Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.

May 16, 2017 07:58 am ET

BioSyent Schedules Q1 2017 Earnings Release for May 25, 2017

May 01, 2017 08:00 am ET

FeraMAX(R) Named #1 by Canadian Physicians and Pharmacists for Second Consecutive Year

Editors note: There is one image accompanying this press release.

May 01, 2017 07:58 am ET

FeraMAX(R) Named #1 by Canadian Physicians and Pharmacists for Second Consecutive Year

Editors note: There is one image accompanying this press release. BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that FeraMAX® has been named the #1 recommended iron supplement brand in a national survey of...

Apr 24, 2017 08:00 am ET

BioSyent to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference on May 1st, 2017 at 3:00pm ET at the Sheraton Centre Toronto Hotel, Toronto, Ontario. Mr. Rene Goehrum, President and CEO, will present to investors an overview of BioSyent's business and corporate activities. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference on May 1st and 2nd. These one-on-one meetings can be requested by attendees through the online conference

Apr 24, 2017 07:58 am ET

BioSyent to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2017 04:00 pm ET

BioSyent Extends In-License Agreement for Cathejell(R)

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. ("BioSyent Pharma"), has extended its License, Distribution and Supply Agreement with its European partner, Pharmazeutische Fabrik Montavit Ges.m.b.H., which gives BioSyent Pharma exclusive Canadian rights to the Cathejell(R) Jelly 2% product until March 31, 2024.

Apr 20, 2017 03:58 pm ET

BioSyent Extends In-License Agreement for Cathejell(R)

Mar 15, 2017 08:00 am ET

BioSyent Releases Results for Fourth Quarter and Full Year 2016

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three and twelve months ended December 31, 2016. Key highlights include:

Mar 15, 2017 07:58 am ET

BioSyent Releases Results for Fourth Quarter and Full Year 2016

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2016. Key highlights include: 2016 Net Revenues of $17,922,270...

Mar 06, 2017 08:00 am ET

BioSyent Schedules Fourth Quarter 2016 Earnings Release for March 15, 2017

BioSyent Inc. ("BioSyent", "the Company") (TSX VENTURE: RX) will be reporting its financial results for the fourth quarter and fiscal year ended December 31, 2016 on Wednesday, March 15, 2017. A presentation on the Company's fourth quarter 2016 results by Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.

Mar 06, 2017 07:58 am ET

BioSyent Schedules Fourth Quarter 2016 Earnings Release for March 15, 2017

Dec 12, 2016 07:00 pm ET

BioSyent Announces Sale of Shares

BioSyent Inc. ("BioSyent", "the company") (TSX VENTURE: RX) President & CEO Rene Goehrum has advised the company that he has sold 300,000 shares in a single block to an existing institutional shareholder of BioSyent in a non-open market transaction. Mr. Goehrum continues to be the largest shareholder of BioSyent, holding a total of 2,245,261 BioSyent shares either directly or indirectly.

Dec 12, 2016 06:58 pm ET

BioSyent Announces Sale of Shares

BioSyent Inc. ("BioSyent", "the company") (TSX VENTURE:RX) President & CEO René Goehrum has advised the company that he has sold 300,000 shares in a single block to an existing institutional shareholder of BioSyent in a non-open market...

Nov 23, 2016 08:00 am ET

BioSyent Releases Results for Third Quarter and First Nine Months of 2016

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three and nine months ending September 30, 2016. Key highlights include:

Nov 23, 2016 07:58 am ET

BioSyent Releases Results for Third Quarter and First Nine Months of 2016

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three and nine months ending September 30, 2016. Key highlights include: First nine months (YTD) 2016 Net Revenues...

Nov 14, 2016 08:00 am ET

BioSyent Pharma Launches New Urgent Care Product

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has launched a new urgent care product, phenylephrine hydrochloride injection in the Aguettant System(R) pre-filled syringe ("Phenylephrine PFS"), for use in hospitals and acute care settings. The Company has already received two purchasing organization listings which give it access to more than 800 hospitals in Canada. In response to customer orders, shipments of the product have commenced.

Nov 14, 2016 07:58 am ET

BioSyent Pharma Launches New Urgent Care Product

Nov 08, 2016 08:00 am ET

BioSyent Signs Exclusive Agreement for New Women's Health Product

BioSyent Inc. ("BioSyent")(TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma International Inc. has signed an exclusive License and Supply Agreement with a European partner for a new product in the women's health therapeutic area for the Canadian market. The product has been approved in Europe and in certain other markets around the world and will be launched in Canada after approval by Health Canada. BioSyent intends to submit the dossier seeking marketing approval of the product to Health Canada in 2017.

Nov 08, 2016 07:58 am ET

BioSyent Signs Exclusive Agreement for New Women's Health Product

Nov 07, 2016 08:00 am ET

BioSyent Schedules Q3 2016 Earnings Release for November 23, 2016

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) will be reporting its financial results for the three and nine months ending September 30, 2016 on Wednesday, November 23(rd). A presentation on the Company's third quarter 2016 results by Mr. Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.

Nov 07, 2016 07:58 am ET

BioSyent Schedules Q3 2016 Earnings Release for November 23, 2016

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) will be reporting its financial results for the three and nine months ending September 30, 2016 on Wednesday, November 23rd. A presentation on the Company's third quarter 2016 results by Mr. René...

Sep 15, 2016 09:15 am ET

BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 815%

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that Canadian Business and PROFIT today named BioSyent to the 28th annual PROFIT 500, the definitive ranking of Canada's Fastest-Growing Companies. Published in the October issue of Canadian Business and at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their five-year revenue growth.

Sep 15, 2016 09:13 am ET

BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 815%

Aug 12, 2016 08:00 am ET

BioSyent Releases Q2 and H1 2016 Results

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three and six months ending June 30, 2016. Key highlights include:

Aug 12, 2016 07:58 am ET

BioSyent Releases Q2 and H1 2016 Results

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three and six months ending June 30, 2016. Key highlights include: Second quarter (Q2) 2016 Net Revenues of...

Aug 08, 2016 08:00 am ET

BioSyent Schedules Q2 2016 Earnings Release for August 12, 2016

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) will be reporting its financial results for the three and six months ending June 30, 2016 on Friday, August 12th at 8:00am (EST). A presentation on the Company's second quarter 2016 results by Mr. Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.

Aug 08, 2016 07:58 am ET

BioSyent Schedules Q2 2016 Earnings Release for August 12, 2016

May 27, 2016 08:00 am ET

BioSyent Releases Q1 2016 Results

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three months ending March 31, 2016. Key highlights include:

May 27, 2016 07:58 am ET

BioSyent Releases Q1 2016 Results

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three months ending March 31, 2016. Key highlights include: First quarter (Q1) 2016 Net Revenues of $3,772,463...

May 26, 2016 08:00 am ET

FeraMAX(R) Named #1 by Canadian Doctors and Pharmacists

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that its FeraMAX(R) brand was recently named as the #1 recommended over-the-counter ("OTC") iron supplement brand in a national survey of Canadian physicians and pharmacists.

May 26, 2016 07:58 am ET

FeraMAX(R) Named #1 by Canadian Doctors and Pharmacists

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its FeraMAX® brand was recently named as the #1 recommended over-the-counter ("OTC") iron supplement brand in a national survey of Canadian physicians and...

May 25, 2016 02:00 pm ET

IIROC Trading Resumption - RX

VANCOUVER, May 25, 2016 /CNW/ - Trading resumes in:

May 25, 2016 01:44 pm ET

IIROC Trading Halt - RX

VANCOUVER, May 25, 2016 /CNW/ - The following issues have been halted by IIROC:

May 25, 2016 12:53 pm ET

BioSyent Signs Exclusive Distribution Agreement for Two New Cardiovascular Products

May 25, 2016 12:53 pm ET

BioSyent Signs Exclusive Distribution Agreement for Two New Cardiovascular Products

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma International Inc. has signed an exclusive Distribution Agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market. The products have been approved in Europe and in certain other markets around the world and will be launched in Canada if approval is granted by Health Canada. BioSyent intends to submit the dossier seeking marketing approval of the products to Health Canada in 2016.

May 25, 2016 10:01 am ET

BioSyent Schedules Q1 2016 Earnings Release for May 27, 2016

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) will be reporting its financial results for the three months ending March 31, 2016 on Friday, May 27, 2016 at 8:00am (EST). A presentation on the Company's first quarter 2016 results by Mr. Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.

May 25, 2016 10:01 am ET

BioSyent Schedules Q1 2016 Earnings Release for May 27, 2016

May 05, 2016 08:00 am ET

BioSyent Pharma Receives Health Canada Approval for New Urgent Care Product Using the Aguettant System(R)

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX)(OTC PINK: BIOYF) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received approval from Health Canada for a new urgent care product, phenylephrine hydrochloride injection in the Aguettant System(R) pre-filled syringe (PFS), for use in hospitals and acute care settings.

May 05, 2016 07:58 am ET

Ad blocking detected

BioSyent Inc. (V:RX)

Business Focus: Pharmaceuticals (NEC)